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Abstract
Background: Matrix metalloproteinase (MMP) is known to be involved in the initial and progressive stages of cancer
development, and in the aggressive phenotypes of cancer. This study examines the association of single nucleotide
polymorphisms in promoter regions of MMP-1 and MMP-3 with susceptibility to oral squamous cell carcinoma (OSCC).
Methods: We compared 170 Japanese OSCC cases and 164 healthy controls for genotypes of MMP-1 and MMP-3.
Results: The frequency of the MMP-1 2G allele was higher and that of the 1G homozygote was lower in the OSCC cases
(p = 0.034). A multivariate logistic regression analysis revealed that subjects who were 45 years old or older had a
significantly increased (2.47-fold) risk of OSCC (95%CI 1.47–4.14, p = 0.0006), and those carrying the MMP-1 2G allele
had a 2.30-fold risk (95%CI 1.15–4.58, p = 0.018), indicating independent involvement of these factors in OSCC. One of
the key discoveries of this research is the apparent reduction of the MMP-1 1G/1G and 1G/2G genotype distributions
among the early onset OSCC cases under the ages of 45 years. It should be noted that the tongue was the primary site
in 86.2% of these early onset cases. This could suggest the specific carcinogenic mechanisms, i.e. specific carcinogenic
stimulations and/or genetic factors in the tongue.
Conclusion: Since the 2G allele is a majority of the MMP-1 genotype in the general population, it seems to act as a
genetic pre-condition in OSCC development. However this report suggests a crucial impact of the MMP-1 2G allele in
the early onset OSCC.
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Background
Matrix metalloproteinase (MMP)-1 (Collagenase-1) is a
major proteinase of the MMP  family that specifically
degrades type I collagen, which is a major component of
the extracellular matrix (ECM), as well as other fibrillar
collagens of types II, III, V and IX [1,2]. MMP-3 (Strome-
lysine-1) is responsible for degradation of type IV colla-
gen, which forms the basement membrane, and collagen
V, IX, X [3]. MMP-3  also has a role in activation of
proMMP-1 in tumor tissue into the active form of MMP-1
[4]. Gene expression data in our previous report demon-
strated enhanced expression of MMP  family genes in
OSCC tissues, and suggested correlation of high expres-
sion levels of MMP-1 and MMP-3 with aggressive behav-
ior, such as metastasis, and clinical prognosis [5]. Similar
correlations have been reported in pharyngeal, colon and
various other tumor types [6-8]. Colocalization of MMP-1
and MMP-3 with destruction of ECM in the invasive front
of cancer tissue suggests a direct role in cancer invasion
[9].
It has also been shown that a function of MMPs affects
susceptibility to different kinds of carcinoma. To date,
polymorphisms of the promoter domain have been
described in MMP-1, -3, -9, -12 to influence the expres-
sion level of the genes [10]. A 2G type of single nucleotide
polymorphism (SNP) at -1607 bp site in the promoter
domain of MMP-1 creates a sequence, 5'-GGA-3,' that is
the core recognition sequence of the binding site for Ets
family transcription factors. The 2G type promoter results
in higher transcription activity of the MMP-1 gene than
does a 1G type promoter [11]. A 5A type promoter at -
1171 bp site of MMP-3 is also known to have a twofold
higher transcriptional activity in vitro than that of a 6A
type [12]. It has been documented that the 2G type SNP
of MMP-1  confers increased susceptibility to colorectal
[13], ovarian [14], lung [15], endometrial [16], renal cell
[17] and head and neck [18] cancers; and the 5A type SNP
of MMP-3 is associated with an increased susceptibility to
breast cancer [19].
An in situ hybridization study revealed that MMP-1
expression in normal oral mucosa is controlled at a low
level, whereas a remarkably elevated expression level is
observed in cases of oral epithelial dysplasia, which
becomes even higher in cases of OSCC [20]. It has also
been documented that cases of oral epithelial dysplasia
showing high expression level of MMP-1 developed into
OSCC at higher frequency than cases with low expression
of MMP-1 [21]. Taking all the observations noted above
into consideration, it seems likely that MMPs may serve as
key factors in all stages of the OSCC progression from car-
cinogenesis in the early precancerous condition to the
advanced invasive and metastatic phases.
The purpose of this study is to document the effect of
genomic polymorphisms of MMP genes in the develop-
ment of OSCC. We compared genotype distribution in the
promoter domains of the functional SNPs that influence
the transcriptional activity of MMP-1 and MMP-3 between
OSCC patients and healthy control groups. Multivariate
analysis was effectively used to assess correlations among
parameters such as OSCC, the genotypes, age and sex. In
this report, we describe the role of functional SNP of the
MMP-1 gene in susceptibility to OSCC and, as a remarka-
ble finding; we discuss the crucial impact of the MMP-1
2G allele in the development of OSCC in younger individ-
uals.
Methods
Study subjects
The tested cases were all unrelated native Japanese com-
prising 170 cases of OSCC (107 males, 63 females; aver-
age age 56.5 ± 13.9 years) who were histopathologically
diagnosed as differentiated squamous cell carcinoma. The
controls comprised 164 (104 males, 60 females) healthy
subjects who did not have a history of malignant tumors
and were frequency-matched to the cases by age (± 5 years;
average age 51.5 ± 14.7 years). All OSCC subjects were
patients who had been treated in the Dental Department
of Niigata University Medical and Dental Hospital, Spe-
cial Dental Care and Oral Surgery, Shinshu University
Hospital, and Division of Oral Surgery, Nagaoka Red
Cross Hospital.
Blood samples were taken after obtaining the patients'
informed consent to participate in the study and proc-
essed anonymously. All cases were diagnosed histopatho-
logically as OSCC. The study protocol was approved by
the ethics committees of each institution.
Genotyping of MMP-1 and MMP-3
5 ml of blood was obtained from the subjects and used as
the source of peripheral blood lymphocytes. 0.2% NaCl
was added for destruction of red blood cells, followed by
addition of TNE buffer, 10% SDS and Proteinase K
(MERCK Co., Darmstadt, Germany). After incubation at
58°C for more than six hours, genomic DNA was
extracted by phenol-chloroform treatment and ethanol
precipitation. The reaction was performed in a 25 µl vol-
ume made up of 70 ng genomic DNA, 2.25 µl of the spe-
cific forward/reverse primer (10 µM), 1 µl of TaqMan®
MGB probes (5 µM), 12.5 µl of TaqMan® Universal Master
Mix (Applied Biosystems, Foster City, CA, USA). PCR
cycling conditions were 10 min of initial denaturation at
95°C followed by 35 cycles of 15 sec denaturation at
92°C and 1 min of one step annealing/extension at 60°C
for  MMP-1  or 62°C for MMP-3  (ABI Prism® 7900 HT
Sequence Detection System, Applied Biosystems). Combi-
nation of the probe/primer used for the MMP-1 SNP were:BMC Cancer 2007, 7:187 http://www.biomedcentral.com/1471-2407/7/187
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Forward primer, 5'-TGCCACTTAGATGAGGAAATTG-
TAGT-3' and reverse primer, 5'-ACACTTTCCTCCCCTTAT-
GGATTC-3', TaqMan®  MGB probes, FAM for 1G, 5'-
ATAATTAGAAAGATATGACTTATC-3' and VIC for 2G, 5'-
ATAATTAGAAAGGATATGACTTAT-3'; used for the MMP-
3  SNP were: Forward primer, 5'-ACATCACTGCCAC-
CACTCTGTT-3' and reverse primer, 5'-GGCACCT-
GGCCTAAAGACATT-3', TaqMan® MGB probes, FAM for
5A, 5'-AAGACATGGTTTTTC-3' and VIC for 6A, 5'-AGA-
CATGGTTTTTTC-3'.
Statistical analysis
The Chi-square test was used to examine the differences in
genotype distribution of the MMP-1 and MMP-3 promot-
ers between the OSCC cases and control groups, and to
estimate correlation or synergistic effects of MMP-1 geno-
types with regard to clinical consequences as well as envi-
ronmental factors among the OSCC cases. A p-value of <
0.05 was considered as statistically significant. Univariate
analysis was performed by Fisher's exact test (two-sided)
on gender, carrier state of MMP-1 1G allele (1G+ or 1G-)
and 2G allele (2G+ or 2G-) between the OSCC and con-
trol groups. In the consideration of latent interrelations
between factors, the effects of MMP-1 2G allele, age and
gender were estimated by a multivariate logistic regression
model. For each parameter, the OSCC risk was accounted
by Odds Ratios (OR) and 95% Confidence Intervals (95%
CI). All of the statistical analyses were performed using
the SPSS 11.5J software package (SPSS Japan Inc., Tokyo,
Japan).
Results
Genotype distributions of MMP-1 and MMP-3 promoter 
polymorphisms in OSCC cases and control groups
The genotype distributions of the promoter SNPs in
MMP-1 and MMP-3 genes did not indicate a departure
from the Hardy-Weinberg equilibrium when they were
examined separately in the OSCC (n = 170) and control
(n = 164) groups, or in all the samples combined (n =
334) (χ2 < 3.84, p > 0.05). The frequency of 1G/2G or 2G/
2G promoter genotypes having the 2G allele, which is
associated with a high MMP-1 expression level, was signif-
icantly higher in the OSCC group, and the frequency of
the 1G/1G homozygote was lower than that of the control
group (p = 0.034, Table 1). On the other hand, no differ-
ence in MMP-3 genotype distribution (5A/5A, 5A/6A, and
6A/6A) was detected between the OSCC case and control
groups.
Association between MMP-1 promoter genotypes and 
various clinical parameters
MMP-1 promoter genotypes of OSCC cases were stratified
by clinical parameters including gender, age (Table 2), T
category, lymph-node metastasis (N category), tumor
location in the oral cavity, status of alcohol intake and
smoking (Table 3). A significant association was detected
only between the age and MMP-1 genotype, which sug-
gests accumulation of older age patients with the 1G
allele, or young age patients with the 2G allele. Figure 1
shows the age distribution pattern of subjects with MMP-
1 promoter genotypes in OSCC groups, demonstrating a
remarkable reduction of the 1G/1G and 1G/2G genotype
distributions in OSCC cases less than 45 years and 35
years old. Receiver operating characteristic (ROC) curve
consistently exhibited that the 45 years of age could be an
optimal cutoff value of the age at which to stratify the
young OSCC from the older bracket in following analyses.
It was of considerable interest to notice that the MMP-1
promoter genotype has a remarkable difference in distri-
bution between subjects over and under 45 years of age. A
Table 2: Age and gender distribution in relation to alleles in cases and controls
OSCC cases Controls
2G/2G 1G/2G 1G/1G p 2G/2G 1G/2G 1G/1G p
Age* 54.8 ± 15.1 57.5 ± 13.2 60.1 ± 10.9 0.277 52.2 ± 14.8 52.3 ± 14.5 48.1 ± 14.2 0.387
Gender#
males 46 (59.7%) 53 (67.1%) 8 (57.1%) 0.570 38 (59.4%) 46 (64.8%) 20 (69%) 0.640
females 31 (40.3%) 26 (32.9%) 6 (42.9%) 26 (40.6%) 25 (35.2%) 9 (31%)
Data are expressed as mean ± SD or number of subjects (%).
* One-way ANOVA test.
# χ2 test.
Table 1: MMP-1and MMP-3 genotype distribution in OSCC cases 
and controls
OSCC cases 
(n = 170)
Controls 
(n = 164)
p
MMP-1
2G/2G 77 (45.3) 64 (39.0) 0.034
1G/2G 79 (46.5) 71 (43.3)
1G/1G 14 (8.2) 29 (17.7)
MMP-3
5A/5A 3 (1.8) 8 (4.9) 0.188
5A/6A 50 (29.4) 54 (32.9)
6A/6A 117 (68.8) 102 (62.2)
The data were analyzed by the χ2 test.BMC Cancer 2007, 7:187 http://www.biomedcentral.com/1471-2407/7/187
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significant difference was demonstrated in susceptibility
to OSCC in individuals less or more than 45 years old (p
= 0.002, OR = 2.26, 95%CI = 1.35–3.79) (Table 4). No
association was observed with the 1G allele (1G/1G and
1G/2G;  p  = 0.294, OR = 1.29, 95%CI = 0.84–2.00,
whereas a significantly elevated risk of OSCC was exhib-
ited with the 2G allele (2G/2G and 1G/2G; p = 0.016, OR
= 2.39, 95%CI = 1.21–4.72. The environmental factors,
alcohol intake and smoking status were stratified with
MMP-1 genotype distributions in OSCC cases, but no sig-
nificant association was demonstrated of either factor
with the MMP-1 genotype distribution (Table 3).
Multivariate analyses of MMP-1 allele frequencies and 
clinical parameters
Logistic regression analysis of OSCC in relation to age,
gender, and presence of the 1G and 2G alleles revealed
that subjects of 45 years old and older had a 2.47-fold sig-
nificantly increased risk of OSCC (p = 0.0006, 95%CI =
1.47–4.14) and that those carrying the MMP-1 2G allele
had a 2.30-fold significantly elevated risk (p  = 0.018,
95%CI = 1.15–4.58). Thus it was demonstrated that age
and the presence of the 2G allele were independently
associated with OSCC onset (Table 5).
Discussion
In this study, we examined SNPs in the promoter regions
of MMP-1 and MMP-3 genes in relation to OSCC risk with
case-control analyses. Significant differences, i.e., high fre-
quency of 2G/2G genotype and decreased frequency of
1G/1G genotype, were observed in the MMP-1 genotype
distribution in OSCC cases (p = 0.034, Table 1). Similarly,
in comparisons of allele frequency a significant correla-
tion was detected between onset of OSCC and genotypes
that carry the MMP-1 promoter 2G allele in homo- or het-
ero-form (p = 0.016, OR = 2.39, 95%CI = 1.21–4.72).
MMP-1 with the 2G type promoter caused a higher expres-
sion level of MMP-1 in tissues [11]. The biological mech-
Table 3: Relation of MMP-1 genotypes to clinical parameters and environmental factors among the OSCC cases
2G/2G n (%) 1G/2G n (%) 1G/1G n (%) p
Total 77 (45.3) 79 (46.5) 14 (8.2)
Gender
Male 46 (45.9) 53 (47.5) 8 (7.4) 0.57
Female 31 (47.2) 26 (41.3) 6 (7.5)
Age
(years ± SD) 54.8 ± 15.1 57.5 ± 13.2 60.1 ± 10.9 0.277*
T category
T1-2 55 (45.1) 58 (47.5) 9 (7.4) 0.78
T3-4 22 (45.8) 21 (43.8) 5 (10.4)
N category
N0 50 (43.9) 53 (46.5) 11 (9.6) 0.607
N1-3 27 (48.2) 26 (46.4) 3 (5.4)
Tumor location
Tongue 45 (54.9) 31 (37.8) 6 (7.3) 0.260#
Lower gingiva 14 (35) 24 (60) 2 (5)
Oral floor 6 (35.3) 9 (52.9) 2 (11.8)
Buccal mucosa 3 (21.4) 9 (64.3) 2 (14.3)
Upper gingiva 7 (53.8) 5 (38.5) 1 (7.7)
Palate 2 (50) 1 (25) 1 (25)
Alcohol intake
Drinker 45 (45.9) 45 (45.9) 8 (8.2) 0.982
Non-drinker 32 (44.4) 34 (47.2) 6 (8.3)
Smoking status
Smoker 39 (44.3) 43 (48.8) 6 (6.8) 0.702
Non-smoker 38 (46.3) 36 (43.9) 8 (9.8)
T and N categories were according to the UICC TNM classification of malignant tumors for lip and oral cavity. The data were analyzed by the χ2.
* One-way ANOVA test.
# Fisher's exact tests.BMC Cancer 2007, 7:187 http://www.biomedcentral.com/1471-2407/7/187
Page 5 of 9
(page number not for citation purposes)
anism of the elevated risk of OSCC as related to the 2G
allele of MMP-1  promoter includes genetic instability,
which is accompanied by the cell cycle activation caused
by a sequence of events led by increased MMP-1 enzyme
activity, i.e. activation of tissue disruption, reconstruction
and resultant release of ECM binding growth factors. The
relationship between MMP-1  promoter polymorphism
and risk of OSCC has been investigated by Lin et al. in a
group of 121 cases [22] and by Cao et al. in a group of 96
cases [23] and by Vairaktaris et al. in a group of 156 cases
[24]. Although both Lin et al. and Cao et al.reported an
elevation of OSCC risk correlated with the MMP-1 2G
allele, further studies were needed to reach a conclusion
mainly because the numbers of cases in the previous stud-
ies were relatively small, and there were differences
between these reports in background analyses on correla-
tion with environmental risk factors, such as smoking and
areca use. In this study, significant correlations were
found between the presence of the MMP-1 promoter 2G
allele and increased OSCC risk among 170 Japanese
OSCC patients. These results are consistent with existing
reports on malignant neoplasms in general. It is notable
that a new finding on the molecular function of MMP-1 in
the onset of OSCC was obtained from the characteristic
pattern of the MMP-1 promoter genotype distribution in
younger patients.
Interestingly, Vairaktaris et al. reported an increased risk of
oral cancer with MMP-1 1G/2G polymorphism [24]. The
discrepancy of the results of the Chinese studies and our
report on one hand and the European (German and
Greek) study on the other hand may be explained by the
diverse ethnic background of the different studied popu-
lations. Another point of difference is the fact that their
patient sample included patients with positive family his-
tory of thrombophilia.
The observed bias of the average age by the MMP-1 pro-
moter genotype among the 170 OSCC cases of this study
suggested an influence of the MMP-1 promoter 2G allele
on the age of OSCC onset. The scatter plot of age on the
MMP-1 promoter genotypes also revealed disappearance
of the 1G/1G-genotype distribution among the OSCC
cases under 45 years old. In agreement with this observa-
tion, the ROC analysis suggested that the age of 45 years
is the borderline age above which a change occurs in the
incidence of OSCC. Although the specific reasons for
these results have not been clarified, they suggest that
some kind of biological conditions related to carcinogen-
esis have initiated around the age of 45. Carcinogenesis is
caused by synergistic effects of various factors [25,26]. The
multivariate logistic regression analysis showed that aging
Age distribution of the MMP-1 genotypes in 170 OSCC cases  between the ages of 20 and 80 years Figure 1
Age distribution of the MMP-1 genotypes in 170 
OSCC cases between the ages of 20 and 80 years. The 
frequency of the 1G/1G genotype is notably low. Note the 
clear reduction of the 1G/1G and 1G/2G genotype distribu-
tions in individuals under the ages of 45 and 35 years, respec-
tively.
1G/1G     1G/2G      2G/2G
A
g
e
Table 4: Univariate analysis of predictive factors
OSCC Controls p OR (95% CI)
Age 0.002 2.26 (1.35–3.79)
<45 29 52
45 141 112
Gender 1.000 0.98 (0.63–1.53)
Male 107 104
Female 63 60
1Ga 0.294 1.29 (0.84–2.00)
- 77 64
+ 93 100
2Gb 0.016 2.39 (1.21–4.72)
- 14 29
+ 156 135
a: 1G- denotes 2G/2G, and 1G+ denotes 1G/1G or 1G/2G. b: 2G- 
denotes 1G/1G, and 2G+ denotes 2G/2G or 1G/2G.
Data were analyzed by Fisher's exact test. The odds ratio and 95% CI 
were calculated.BMC Cancer 2007, 7:187 http://www.biomedcentral.com/1471-2407/7/187
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and presence of the MMP-1 2G allele (i.e., 2G/2G or 1G/
2G) are independently involved in onset of OSCC. In fact,
it was clarified that the significance of the presence of the
MMP-1 2G allele was lower in the subject group 45 years
old or older (p = 0.238, OR = 1.65, 95% CI = 0.75–3.55),
and that the impact of the allele was highly significant in
the younger group, which was under 45 years old (p =
0.014, OR = 9.67, 95% CI = 1.20–78.15) (data not
shown).
As concrete causes of OSCC, mainly tobacco smoking and
alcohol usage and, in some cases, viral infections have
attracted attention as environmental causative factors
[25,27]. It has been suggested that tobacco smoking and
alcohol usage alone may not explain the mechanism of
the entire early onset of OSCC, because the duration of
exposure to these risk factors in young OSCC patients is
shorter than in the older group, and also because there are
some cases with stable incidence that have no known risk
factors [28]. The association with smoking and habitual 
drinking has been supported as the risk factors of OSCC,
which generally shows a higher incidence in older age, but
other investigators believe that the mechanism of the early
onset OSCC is fundamentally different from that of eld-
erly onset OSCC [25]. Cao et al. considered the relation-
ship with smoking as a behavioral risk factor and the
MMP-1  2G allele as a genetic risk factor in the OSCC
group [23]. In lung cancer, it has been similarly shown
that a genetic factor of the MMP-1 promoter 2G allele
increases the risk of cancer that occurs in a tobacco-usage-
dependent manner only in cases with a history of tobacco
use. These reports support the role of MMP-1 promoter
polymorphism as an endogenous background factor, in
contrast to exogenous environmental factors [15]. How-
ever, no evidence to support a notion of synergistic inter-
actions between risk factors, such as habitual smoking
and drinking and MMP-1  promoter polymorphism in
OSCC cases, was shown in this study. Further investiga-
tions with regard to frequency and duration of exposure
are required to consider interactions between environ-
mental factors and multiple genetic background factors.
Examples are known of malignant neoplasms caused by
genetic factors, for example, mutations in RB in Retino-
blastoma [29], p53 in Li-Fraumeni Syndrome [30], and
APC in familial adenomatous polyposis [31]. There are
also reports of mutations in BRCA1 and BRCA2, which
affect familial breast cancer occurrence, though their pen-
etrance is low [32]. These are neoplasms that are all
caused by loss-of-function mutations in molecules func-
tionally classified as tumor-suppressor genes, and they are
characterized by familial, juvenile or young onset and
may be multicentric or bilateral. Although incidents are
rare in the population, they are examples of germline
mutations that directly involve heterofamilial tumorigen-
esis.
By contrast, the MMP-1 promoter 2G allele is a genetic
polymorphism that exists at the high allele frequency of
80% to 90% in the general population. It is possible to
call this a hereditary trait that is shared among races or
humans in general. Other genetic factors that are classified
into similar polymorphism as MMP-1  have also been
reported, such as Cyclin D1 (CCND1) in head and neck
squamous cell carcinoma (HNSCC) and colorectal cancer
[33,34], xeroderma pigmentosum complementary group
D (XPD), DNA damage binding protein 2 (DDB2), and
MMP-9 in lung cancer [35-37]. Similar to the effects of
mutations in tumor suppressor genes, diversity in gene
expression level and molecular structure caused by genetic
polymorphisms affect monitoring and repair mechanism
of DNA replication, as well as control of the cell cycle, ulti-
mately resulting in genetic instability. The common
mechanism of carcinogenesis caused by those genetic fac-
Table 5: Multivariate analysis of factors affecting OSCC
A Results of factors affecting OSCC
β coefficient OR 95% CI of OR p
2G+ 0.83 2.30 (1.15–4.58) 0.0180
Age 0.90 2.47 (1.47–4.14) 0.0006
B Results showing the alleles independently associated with OSCC (adjusted for age and gender).
Allele β coefficient OR 95% CI of OR p
1G/2G 0.782 2.187 (1.06–4.51) 0.034
2G/2G 0.907 2.476 (1.20–5.13) 0.015
A: 2G+ : 2G- = 0, 2G+ = 1
Age : <45 = 0, 45 = 1
B: With adjustment for age and gender Alleles are included as multinomial variables with categorical coding in reference to 1G/1G allele.
% concordance = 74.9%.
Hosmer-Lemeshow Goodness-of-fit test: χ2 test = 0.996 ; p = 0.998BMC Cancer 2007, 7:187 http://www.biomedcentral.com/1471-2407/7/187
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tors is an elevated carcinogenic risk due to this genetic
instability.
As examples of genetic polymorphisms that affect onset
age of cancers other than that examined in this study,
some reports discuss MMP-1 and DDB2 in lung cancer
[15,36], and CCND1  in HNSCC and colorectal cancer
[33,34]. These genetic factors, on the other hand, are
present in patients with cancer as well as in the general
population at certain frequencies. Therefore, it is hard to
conclude that these genetic factors are the primary factors
in early onset carcinogenesis, unlike germline single-gene
mutations in Rb and APC that induce juvenile or early
onset of cancers with high penetrance. Aging brings expo-
sure to various carcinogenic factors and is associated with
inevitable accumulation of genetic and epigenetic modifi-
cations of genes. These accumulations interact synergisti-
cally with biological background factors on the host side,
and consequently cancer may develop [26,38]. It seems
that inherited genetic factors play a larger role in develop-
ment of early onset cancer that has undergone a relatively
short duration of exposure to carcinogen through envi-
ronment and lifestyle habits. Therefore, it is conceivable
that the impact of these genetic factors would appear
more directly in younger than in older cases, although we
still expect a synergistic involvement of various environ-
mental and genetic factors. Nevertheless, because of the
disappearance ofthe MMP-1  1G allele distribution
observed in the OSCC cases with a clear boundary under
the age of 45 years, the MMP-1 promoter 2G allele should
be recognized as an essential genetic precondition for the
development of early onset OSCC.
It is said that an onset age of 45 years and younger
accounts for about 6% of OSCC cases [27]. It should be
noted that in this study we found that the tongue was the
primary site in 25 cases (86.2%) of 29 early onset OSCC
cases in individuals under 45 years old. This primary site
was obviously different from that in patients 45 years old
and older in whom we noted 57 cases of tongue cancer
(40.4%) out of 141 OSCC cases. Similar tendencies have
been reported in previous studies [39,40]. These findings
suggest the possibility that each primary tumor sites in the
oral cavity may be associated with differences in cancer
susceptibility, specific carcinogenic stimulation, or genetic
background. However, no environmental or genetic fac-
tors specific to a particular site of the oral mucosa have
been identified for OSCC. It is conceivable that it would
be important to carry out further investigations on genetic
and environmental risk factors for each anatomical site of
the oral regions, though we are not able to discuss this
aspect of OSCC because the number of cases was inade-
quate in this study.
Conclusion
The number of cases in this study was relatively small;
therefore, the conclusions may still be contingent upon
confirmation in a larger study. To evaluate the conclusive
impact of MMP-1  on OSCC risk, a sufficiently large
number of cases or consistency among results from multi-
ple age adjusted studies would be needed. Furthermore,
although the MMP-1 promoter SNP-based determination
of OSCC susceptibility has the potential to become a use-
ful clinical tool, it is necessary to add a greater diversity of
information for practical use. In the future, improvements
in diagnosis of susceptibility and clinical application
could become possible by incorporating multiple genetic
and environmental risk factors into the prediction model
for cancer occurrence. Information about the risk of vari-
ous types of malignant neoplasm as well as OSCC is use-
ful for prevention and early detection of cancer or for
monitoring of postoperative recurrence. A diagnostic sys-
tem for evaluating cancer risk is vital not only for
improvement in treatment techniques but also as a theo-
retical foundation to build strategies for cancer preven-
tion.
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